All In Biotech

Drug Trial Radar · NCT03814291

A Dose Escalation Study of IBI302 in Patients With Wet Age-related Macular Degeneration

A Dose Escalation Phase I Clinical Study to Evaluate the Tolerability and Safety of IBI302 in Patients With Wet Age-related Macular Degeneration (AMD)

Last checked: Nov 19, 2026Latest source record: Apr 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

31

Actual

Start

Apr 15, 2019

Primary completion

Mar 5, 2020

Study completion Apr 10, 2020

Sponsor

Sponsor type
Industry
First posted
Jan 24, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed for single-center, open-label, dose escalation phase I trial to evaluate the safety and tolerability of a single intravitreal injection of IBI302 in patients with wet AMD.

Conditions

  • Neovascular Age-related Macular Degeneration

Interventions

  • IBI302Drug

    0.05mg/eye;Intraocular injection

  • IBI302Drug

    0.15mg/eye;Intraocular injection

  • IBI302Drug

    0.5mg/eye;Intraocular injection

  • IBI302Drug

    1mg/eye;Intraocular injection

  • IBI302Drug

    2mg/eye;Intraocular injection

  • IBI302Drug

    4mg/eye;Intraocular injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety evaluation indicatorsTime frame: Baseline to Day43

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai General Hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.